权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a New Methodology for Pancreatic Diagnosis in Nuclear Medicine.

核医学胰腺诊断新方法的开发。

基本信息

批准号：
01570589
负责人：
MAGATA Yasuhiro
金额：
$ 1.09万
依托单位：
Kyoto University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1989
资助国家：
日本
起止时间：
1989 至 1990
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-01570589/
关键词：
Pancreas Nuclear Medicine PET SPECT Diagnosis Radiopharmaceutical 放射性医薬品 Cー11 Nー13 Iー123 膵癌膵炎ポジトロン断層法

项目摘要

1. Synthesis of new radiopharmaceuticals for pancreatic diagnosis and their basic researchDrug design and synthesis of some suitable compounds as pancreatic imaging agents were performed and their usefulness for pancreas diagnostic radiopharmaceuticals were investigated.(1) Some problems of [S-methyl-C-11]-L-methionine which has been used as a pancreas diagnostic agent for PET study were clarified. It was demonstrated that the best C-11 labeuing position was the carboxy1 group of the methionine for the quantitative analysis with PET.(2) Glucose is well known as an important energy source for all organs. On this basis, a new glucose derivative with an interaction to hexokinase phosphorylation reaction was developed.(3) We have found that N-13-ammonia rapidly accumulated in the human pancreas. In this study, the pancreatic uptake and metabolism of N-13-ammonia was investigated and its usefulness for pancreas imaging was demonstrated.2. Development of methods for the quantitative analysis of the pancreas metabolic functions and their clinical research(1) Differential diagnosis of pancreas cancer from chronic pancreatitis has been difficult with X-ray CT. In this study, only the malignant lesions of the pancreas showed increased uptake of F-18-2-fluoro-2-deoxy-glucose (FDG) was considered to be useful for differential diagnosis between pancreas cancer and chronic pancreatitis.(2) C-11-methionine was shown to be useful for assessment of the pancreas function though the difficulty of quantitative analysis using C-11-methionine in the pancreas was shown in the basic research (1-(1)).(3) It was demonstrated that the dynamic PET study with O-15-water is a promising method to measure pancreas blood flow quantitatively in various disease.(4) HIPDM was developed as a brain perfusion imaging agent. In this study, I-123-HIPDM was indicated to have clinical potential as a human pancreas imaging agent.

1.新型胰腺诊断放射性药物的合成及其基础研究本论文设计合成了一些适合作为胰腺显像剂的化合物，并对其作为胰腺诊断放射性药物的应用进行了研究。(1)本文阐明了[S-甲基-C-11]-L-蛋氨酸作为胰腺诊断剂在PET研究中存在的一些问题。结果表明，C-11标记的最佳位置是蛋氨酸的羧基，适合PET定量分析。(2)众所周知，葡萄糖是所有器官的重要能量来源。在此基础上，开发了一种新的葡萄糖衍生物，它与己糖激酶磷酸化反应有相互作用。(3)我们已经发现，N-13-氨迅速积累在人类胰腺。本研究探讨了胰腺对N-13-氨的摄取和代谢，并证实了其在胰腺显像中的作用.胰腺代谢功能定量分析方法的建立及其临床研究（1）胰腺癌与慢性胰腺炎的鉴别诊断一直是X线CT的难点。在本研究中，只有胰腺恶性病变显示F-18-2-氟-2-脱氧葡萄糖（FDG）摄取增加，才被认为有助于胰腺癌和慢性胰腺炎的鉴别诊断。(2)尽管在基础研究中显示了在胰腺中使用C-11-甲硫氨酸进行定量分析的困难（1-（1）），但C-11-甲硫氨酸被证明可用于评估胰腺功能。(3)结果表明，O-15-水动态PET研究是一种很有前途的方法来定量测量胰腺血流量在各种疾病。(4)HIPDM被开发为脑灌注显像剂。在这项研究中，I-123-HIPDM被认为具有作为人类胰腺显像剂的临床潜力。